Clinical trials: Benign Prostate Hypertrophy(BPH)
- Condition Benign Prostate Hypertrophy(BPH)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Benign Prostatic Hyperplasia, Enlarged Prostate
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
The purpose of this study is to investigate the efficacy and safety of once daily tadalafil when taken with finasteride as a treatment for men with signs and symptoms of Benign Prostatic Hyperplasia and demonstrable prostate…
- Trial name
- NCT01139762
- Testing
- Tadalafil, Finasteride
- Where
- 65 sites in United States, Argentina and 11 more
- Volunteers
- 696 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia (BPH)
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00970632
- Testing
- Tadalafil 5 mg, Tamsulosin
- Where
- 44 sites in Australia, Austria and 8 more
- Volunteers
- 511 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
GreenLight XPS Laser System Retrospective Chart Review
The purpose of this study is to gain information on the safety, efficacy, and quality of life in subjects who have had the GreenLight XPS procedure.
- Trial name
- NCT02139969
- Testing
- GreenLight XPS Laser System
- Where
- 6 sites in United States, Canada
- Volunteers
- 956 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
This randomized, double-blind, placebo-controlled, six-month parallel-group study assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH) , followed by a 12-month…
- Trial name
- NCT00527605
- Testing
- Dutasteride 0.5mg capsule
- Where
- 12 sites in China
- Volunteers
- 253 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study will evaluate the safety and efficacy of intraprostatic administration of botulinum toxin Type A (BOTOX®) compared with placebo to treat urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT01107392
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 8 sites in United States, Canada and 6 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Acute Urinary Retention, Benign Prostatic Hyperplasia
Prostatic Urethral Lift in Subject With Acute Urinary Retention
Assess feasibility and safety of the Prostatic Urethra Lift (PUL) procedure in patients with acute urinary retention secondary to benign prostatic hyperplasia (BPH).
- Trial name
- NCT03194737
- Testing
- UroLift System Procedure
- Where
- 6 sites in United Kingdom
- Volunteers
- 101 people
- Sponsor
- NeoTract, Inc.
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Benign Prostatic Hypertrophy
Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00663858
- Testing
- Cetrorelix 78+78
- Where
- 54 sites in Belarus, Bulgaria and 8 more
- Volunteers
- 420 people
- Sponsor
- AEterna Zentaris
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Embosphere® PROstate Post Market Study
Prostatic artery embolization with Embosphere Microspheres is a relatively new procedure. The goal of this post market study is to evaluate long-term safety and effectiveness in a 'real world' setting.
- Trial name
- PROstate (NCT03527589)
- Testing
- Prostate artery embolization
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 499 people
- Sponsor
- Merit Medical Systems, Inc.
Benign Prostatic Hyperplasia
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
This is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT00894517
- Testing
- Botulinum Toxin Type A
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
This study is designed to compare safety and efficacy of monotherapy finasteride to combination therapy (finasteride and tamsulosin) in Asian men with benign prostatic hyperplasia (BPH) who are at least 50 years of age or older.
- Trial name
- NCT01534351
- Testing
- Finasteride, Tamsulosin
- Volunteers
- 1 people
- Sponsor
- Merck Sharp & Dohme LLC
Benign Prostatic Hyperplasia
Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men
The primary purpose of this clinical trial is to evaluate the change in the International Prostate Symptom Score (IPSS) total score from the beginning of the study to the end of the study for subjects randomized to tadalafil 5mg…
- Trial name
- NCT00540124
- Testing
- Tadalafil, Tamsulosin
- Where
- 5 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study of Tadalafil in Benign Prostatic Hyperplasia
The purpose of this study is to investigate the pharmacokinetics of tadalafil in Japanese and non-Japanese men with Benign Prostatic Hyperplasia (BPH). The safety of tadalafil will also be studied.
- Trial name
- NCT01183650
- Testing
- Tadalafil
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia
A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization
To gain clinical experience with the GreenLight HPS System, a system designed to vaporize and coagulate tissue in the treatment of benign prostatic hyperplasia to reduce lower urinary tract symptoms.
- Trial name
- PVP (NCT00465101)
- Testing
- GreenLight HPS
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- American Medical Systems
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
Nocturia, Prostatic Hyperplasia
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
- Trial name
- NCT00793819
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 215 people
- Sponsor
- Watson Pharmaceuticals
Benign Prostate Hyperplasia, Erectile Dysfunction
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of…
- Trial name
- NCT01937871
- Testing
- 5 mg Tadalafil, 0.2 mg Tamsulosin
- Where
- 14 sites in China
- Volunteers
- 909 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00827242
- Testing
- tadalafil
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company